Instruction for use: Brozaar

Dosage form: coated tablets

Active substance: Losartanum

ATX

C09CA01 Losartan

Pharmacological group

Angiotensin II receptor antagonists (AT1 subtype)

Nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

I50 Heart failure: Exacerbation of chronic heart failure; Shortness of breath with acute heart failure; Acute heart failure; Acute heart failure; Heart failure on the background of intoxication; Heart failure on the background of infections; Acute Heart Failure; Chronic myocardial insufficiency; Cardiac dyspnea

1 tablet, film-coated, contains losartan 0.05 g; In a contour acheikova packing of 10 or 14 pcs., In a cardboard bundle 1, 2 or 3 packs.

Characteristic

Biconvex tablets coated with a film coat, white.

pharmachologic effect

Pharmacological action - antihypertensive.

It blocks the receptors of angiotensin II, reduces OPSS, postnagruzku on the heart, systemic blood pressure and pressure in the small circle of the circulation.

Pharmacodynamics

The effect reaches a maximum in 3-6 weeks.

Pharmacokinetics

Well absorbed, relatively evenly distributed, metabolized with the formation of an active derivative.

Indications of the Brozaar

Arterial hypertension, heart failure.

Contraindications

Hypersensitivity, pregnancy, breast-feeding, children's age.

Side effects

Dizziness, hypotension, hyperkalemia.

Interaction

Diuretics increase the antihypertensive effect (the risk of excessive hypotension increases in patients with dehydration).

Dosing and Administration

Inside, regardless of food intake, once: in patients with arterial hypertension - 0.05-0.1 g / day (with dehydration - at an initial dose of 0.025 g / day); Heart failure in the initial dose of 0.0125 g / day.

Overdose

Symptoms: hypotension, tachycardia, or vagal bradycardia.

Treatment: symptomatic therapy.

Precautionary measures

In case of liver diseases, the dose should be reduced.

Conditions for storage of Brozaar

In a dry, the dark place at a temperature of no higher than 30 ° C

The shelf life of the drug Brozaar

2 years.

Do not use beyond the expiration date printed on the package.